“Bottom line - we really don't have any hard data on Covid that is useable. The 84 patients from CD10 will at best lead to another trial. We need some real data, and it is sitting there compiled and analyzed right this minute. Let's take a look and let the chips fall where they may.”

Great post. NP doesn’t seem akin to unblinding the data, or at least he didn’t during the CC. Correct me if I’m wrong, but I believe someone asked the question about unblinding and he referred to the DSMC’s decision. Maybe with remdesevir’s approval, and pending EUAs/approvals for Regeneron and Eli Lilly, maybe he’ll consider it.